Last reviewed · How we verify
Post-Op Photophobia — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Voltaren | DICLOFENAC | Hisamitsu Pharmaceutical Co., Inc | Nonsteroidal Anti-inflammatory Drug | Prostaglandin G/H synthase 2 | 1988-01-01 | |
| Arthrotec | Diclofenac Sodium | Pfizer | diclofenac | Acid-sensing ion channel 3 | 1988-01-01 | |
| Tham | trometamol | Pfizer | trometamol | 1965-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Post-Op Photophobia
- · 1 drug in Post-Op Photophobia
- Hisamitsu Pharmaceutical Co., Inc · 1 drug in Post-Op Photophobia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Post-Op Photophobia:
- Post-Op Photophobia treatment updates — RSS
- Post-Op Photophobia treatment updates — Atom
- Post-Op Photophobia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Post-Op Photophobia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/post-op-photophobia. Accessed 2026-06-10.
Related
- Post-Op Photophobia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing